Last reviewed · How we verify
Noven Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
3 Phase 2
2 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Diclofenac sodium active topical patch | Diclofenac sodium active topical patch | phase 3 | Nonsteroidal anti-inflammatory drug (NSAID) | Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) | Pain Management / Rheumatology |
Therapeutic area mix
- Pain Management · 2
- Pain Management / Rheumatology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Organon and Co · 2 shared drug classes
- Iroko Pharmaceuticals, LLC · 2 shared drug classes
- Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 2 shared drug classes
- Amneal Pharmaceuticals, LLC · 2 shared drug classes
- Pfizer · 2 shared drug classes
- Antibe Therapeutics Inc. · 1 shared drug class
- Amzell · 1 shared drug class
- Allergan · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Noven Pharmaceuticals, Inc.:
- Noven Pharmaceuticals, Inc. pipeline updates — RSS
- Noven Pharmaceuticals, Inc. pipeline updates — Atom
- Noven Pharmaceuticals, Inc. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Noven Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/noven-pharmaceuticals-inc. Accessed 2026-05-14.